{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:54:18Z","timestamp":1787838858524,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/ftd.0b013e318290eacc","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T11:50:28Z","timestamp":1376394628000},"page":"849-852","source":"Crossref","is-referenced-by-count":43,"title":["Lacosamide Therapeutic Monitoring in Patients With Epilepsy"],"prefix":"10.1097","volume":"35","author":[{"given":"Manuela","family":"Contin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenzo","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmina","family":"Candela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Baruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1734-1140(09)70024-6","article-title":"Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.","volume":"61","author":"Luszczki","year":"2009","journal-title":"Pharmacol Rep"},{"key":"R2-16-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s13318-012-0093-x","article-title":"Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration.","volume":"37","author":"Cawello","year":"2012","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"suppl 7","key":"R3-16-20210129","first-page":"188","article-title":". Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927 abstract.","volume":"43","author":"Horstmann","year":"2002","journal-title":"Epilepsia"},{"key":"R4-16-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","article-title":". Progress report on new antiepileptic drugs: a summary of the ninth Eilat conference (EILAT IX).","volume":"83","author":"Bialer","year":"2009","journal-title":"Epilepsy Res"},{"key":"R5-16-20210129","first-page":"479","article-title":"SPM-927 (Schwarz Pharma).","volume":"6","author":"Hovinga","year":"2003","journal-title":"IDrugs"},{"key":"R7-16-20210129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1528-1167.2010.02751.x","article-title":". Saliva and serum lacosamide concentrations in patients with epilepsy.","volume":"52","author":"Greenway","year":"2011","journal-title":"Epilepsia"},{"key":"R8-16-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0091270009347675","article-title":"No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers.","volume":"50","author":"Cawello","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R9-16-20210129","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1177\/0091270011426875","article-title":"No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers.","volume":"52","author":"Cawello","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R10-16-20210129","first-page":"1129","article-title":". Population pharmacokinetics of LCM in subjects with partial-onset seizures: results from two phase III trials abstract.","volume":"48","author":"Nickel","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R11-16-20210129","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S5189","article-title":"Lacosamide as treatment for partial epilepsy. Mechanisms of action, pharmacology, effects, and safety.","volume":"5","author":"Kellinghaus","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"R12-16-20210129","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":". Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.","volume":"34","author":"Johannensen Landmark","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R14-16-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0920-1211(96)00011-3","article-title":". Dose-dependent metabolism of carbamazepine in humans.","volume":"24","author":"Bernus","year":"1996","journal-title":"Epilepsy Res"},{"key":"R15-16-20210129","first-page":"247","article-title":"The auto-induction of carbamazepine during long-term therapy.","volume":"18","author":"Pynnonen","year":"1980","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"R16-16-20210129","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactionsprinciples and clinical implications.","volume":"8","author":"Johannensen","year":"2010","journal-title":"Curr Neuropharmacol"},{"key":"R17-16-20210129","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/FTD.0b013e3181dcc5fb","article-title":". A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy.","volume":"32","author":"Greenway","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R18-16-20210129","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":". The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials.","volume":"54","author":"Zaccara","year":"2013","journal-title":"Epilepsia"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318290eacc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T12:53:54Z","timestamp":1715864034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201312000-00016"}},"subtitle":["Effect of Concomitant Antiepileptic Drugs"],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318290eacc","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}